NEW YORK (GenomeWeb News) – Agilent Technologies' Dako business will develop companion diagnostic tests for Merck under a master framework agreement announced today.
The tests will be developed for cancer drugs currently in the pharmaceutical firm's development pipeline. Financial and other terms of the deal were not disclosed.
The agreement is the most recent of several CDx deals that Dako has forged with drug manufacturers, including Bristol-Myers Squibb, Genentech, Eli Lilly, and Pfizer.
"With Dako's wide experience in companion diagnostics and its expanded playing field as part of Agilent's Life Sciences and Diagnostics Group, I see great potential in this new agreement," Jacob Thaysen, vice president and general manager for Agilent's diagnostics and genomics business, said in a statement.